CytomX Therapeutics Inc’s recently made public that its CEO McCarthy Sean A. unloaded Company’s shares for reported $42175.0 on Mar 19 ’24. In the deal valued at $2.09 per share,20,223 shares were sold. As a result of this transaction, McCarthy Sean A. now holds 524,481 shares worth roughly $0.86 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, BELVIN MARCIA sold 12,795 shares, generating $26,684 in total proceeds. Upon selling the shares at $2.09, the SVP, Chief Scientific Officer now owns 168,579 shares.
Before that, Landau Jeffrey B sold 6,562 shares. CytomX Therapeutics Inc shares valued at $13,685 were divested by the Chief Business Officer at a price of $2.09 per share. As a result of the transaction, Landau Jeffrey B now holds 110,060 shares, worth roughly $0.18 million.
Piper Sandler upgraded its CytomX Therapeutics Inc [CTMX] rating to an Overweight from a a Neutral in a research note published on May 28, 2024; the price target was increased to $3.50 from $2.25. A number of analysts have revised their coverage, including Wedbush’s analysts, who increased its forecast for the stock in early May from “a Neutral” to “an Outperform”. Jefferies also remained covering CTMX and has increased its forecast on May 06, 2024 with a “Buy” recommendation from previously “Hold” rating. JP Morgan revised its rating on April 22, 2024. It rated CTMX as “a Neutral” which previously was an “an Underweight”.
Price Performance Review of CTMX
On Friday, CytomX Therapeutics Inc [NASDAQ:CTMX] saw its stock fall -1.80% to $1.64. Over the last five days, the stock has lost -3.53%. CytomX Therapeutics Inc shares have risen nearly 5.81% since the year began. Nevertheless, the stocks have fallen -4.65% over the past one year. While a 52-week high of $5.85 was reached on 05/01/24, a 52-week low of $1.04 was recorded on 02/13/24. SMA at 50 days reached $2.1734, while 200 days put it at $1.6964. A total of 0.84 million shares were traded, compared to the trading of 3.51 million shares in the previous session.
Levels Of Support And Resistance For CTMX Stock
The 24-hour chart illustrates a support level at 1.6100, which if violated will result in even more drops to 1.5800. On the upside, there is a resistance level at 1.6800. A further resistance level may holdings at 1.7200. The Relative Strength Index (RSI) on the 14-day chart is 39.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1007, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.78%. Stochastics %K at 15.80% indicates the stock is a buying.
